Author:
Maxim Anca,Ionescu Clara Mihaela
Publisher
Springer Nature Switzerland
Reference26 articles.
1. W. Huang, L. Chen, L. Kang, M. Jin, P. Sun, X. Xin, Z. Gao, Y. H. Bae, Nanomedicine-based combination anticancer therapy between nucleic acids and small molecular drugs. Adv. Drug Delivery Rev. 115(1), 82–97 (2017)
2. M. Eisenstein, New lung-cancer drugs extend survival times. Nature 587, S10–S12 (2020)
3. J.P. Sculier, M. Paesmans, G. Bureau, G. Dabois, P. Libert, G. Vandermoten, O. Van Cutsem, M.C. Berchier, F. Ries et. al, Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the european lung cancer working party. J. Clin. Oncol. 11(10), 1858–1865 (1993)
4. D.S. Thomas, L.H. Cisneros, A.R.A. Anderson, C.C. Maley, In silico investigations of multi-drug adaptive therapy protocols. Cancers 14(11), 2699 (2022)
5. C.M. Rudin, J.T. Poitier, L.A. Byers et al., Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289–297 (2019)